Ubiquitin-proteasome system (UPS) mediated proteolysis is responsible for the degradation of majority of cellular proteins, thereby playing essential roles in maintaining cellular homeostasis and regulating a number of cellular functions. UPS dysfunction was implicated in the pathogenesis of numerous disorders, including neurodegenerative disease, muscular dystrophy, and a subset of cardiomyopathies. However, monitoring in vivo functional changes of the UPS remains a challenge, which hinders the elucidation of UPS pathophysiology. We have recently created a novel transgenic mouse model that ubiquitously expresses a surrogate protein substrate for the UPS. The present study validates its suitability to monitor in vivo changes of UPS proteolytic function in virtually all major organs. Primary culture of cells derived from the adult transgenic mice was also developed and tested for their applications in probing UPS involvement in pathogenesis. Applying these newly established in vivo and in vitro approaches, we have proven in the present study that doxorubicin enhances UPS function in the heart and in cultured cardiomyocytes, suggesting that UPS hyper-function may play an important role in the acute cardiotoxicity of doxorubicin therapy.
and 2 α-rings that flank the β-rings. All peptide cleavage activities reside in the interior face of the 2 β-rings of the 20S proteasome (1) . The UPS targets and destroys specific proteins for purposes of physiological regulation and quality control (2) (3) (4) . In both cases, high specificity is essential and observed. Regulated degradation of specific proteins is often mediated by discrete regions of primary sequence known as degradation signals or degrons (5) , whereas protein quality control involves recognition of structural features common to damaged or misfolded proteins rather than specific features of an individual protein. Some examples of degrons are the destruction box of mitotic cyclins (6, 7) , the PEST domain (a peptide region rich in proline, glutamate, serine, and threonine) of many proteins (8, 9) , and the CL1 degron for channeling proteins for degradation via the Ubc6 and/or Ubc7 subpathways of the UPS in yeast (10, 11) . It was recently proven that the CL1 destabilizes a stable green fluorescence protein (GFP) in a UPS-dependent fashion in the human embryonic kidney (HEK) cells when fused to the C terminus of GFP (12). This suggests that mammalian cells possess Ubc's that function similarly to the Ubc6 and Ubc7 in the yeast.
The proteasomal peptidase activities are measured conventionally by in vitro cleavage of synthetic fluorogenic peptide substrates. These small artificial substrates can diffuse freely into the lumen of the 20S proteasomes, such that assays using them do not reflect changes occurred in other parts of the 26S proteasome. Conceivably, defects in the 19S proteasomes and the α-rings of the 20S proteasomes or deficiency in ubiquitination, as well as other factors outside of the UPS, can also affect the proteolytic function of the UPS. Therefore, a full-length UPS-specific protein substrate would be better for evaluation of the proteolytic function of the UPS. Several surrogate protein substrates of this kind were recently reported for cell culture studies (12) (13) (14) . In intact animals, only one model has been reported by Lindsten et al. (15) . They created a transgenic (TG) mouse model that expresses a GFP carrying a constitutively active degradation signal (Ub G76V -GFP) as a surrogate protein substrate for the UPS. However, their tests showed that Ub G76V -GFP expressed in the heart, brain, and skeletal muscle did not discernibly respond to systemic proteasomal inhibition (15) . Therefore, the Ub
G76V
-GFP model appears not quite suitable for monitoring in vivo UPS function in these important organs. As UPS dysfunction is increasingly being implicated in many disorders of these organs, an effective and direct method to assess in vivo UPS functional status is certainly warranted.
We previously established a system for in situ monitoring UPS function in cultured neonatal ventricular myocytes (NRVMs) using a differently modified GFP, known as GFP u or GFPu (14) . GFPu was engineered by carboxyl-fusion of the degron CL1 (12). In the present study, we have established multiple stable TG mouse lines that ubiquitously express a modified GFP similar to GFPu, referred to as GFPdgn. We performed a series of in vivo and in vitro tests in the present study to validate GFPdgn TG mice as an extremely useful tool for monitoring in vivo dynamic changes in the proteolytic function of the UPS.
Cardiotoxicity is a major hurdle limiting the use of doxorubicin (Dox), a potent anti-cancer agent of the anthracycline family (16) . The mechanism by which Dox (adriamycin) injures the heart remains to be fully elucidated (16) . Oxidative stress from Dox metabolites may be an important cause, but anti-oxidant therapy could not completely abolish the cardiotoxicity, which suggests that additional mechanisms are involved (17, 18) . The proteasome was believed to be used as a carrier for the translocation of Dox from the cytoplasm to the nucleus; thereby its function was compromised by Dox (19, 20) . However, it has also been reported that Dox activates the UPS in leukemia cell lines (21) . Therefore, it remains controversial regarding how Dox affects the proteolytic function of the UPS. Our newly created GFPdgn mouse model provides a unique opportunity to test if and how Dox modulates UPS-mediated proteolysis in cardiomyocytes and the heart.
MATERIALS AND METHODS

Antibodies and reagents
Mouse monoclonal anti-GFP (clone B2) and horseradish peroxidase-conjugated goat anti-mouse secondary antibodies were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). MG-132, MG-262, clasto-lactacystin-β-lactone, were purchased from BIOMOL (Plymouth Meeting, PA). Dox and cycloheximide were obtained from Sigma-Aldrich (St. Louis, MO). The ECL plus enhanced chemiluminescence detection kit was purchased from Amersham Bioscience (Piscataway, NJ). BCA reagents for protein concentration determination were from Pierce Biotechnology, Inc. (Rockford, IL).
Creation of GFPdgn TG mice and genotyping
The coding sequence for a consensus ubiquitination signal sequence (ACKNWFSSLSHFVIHL) known as degron CL1, was fused to the 3′ end of the coding sequence of the enhanced GFP by PCRs. The open reading frame of this modified GFP (referred to as GFPdgn) was inserted into the EcoRI site of the pCAGGS vector (a generous gift from Dr. Jody Martin of Loyola University at Maywood, IL). This placed the GFPdgn behind a hybrid promoter composed of the human cytomegalovirus immediate-early enhancer (CMV-IE) and the chicken β-actin promoter along with its first intron, and in front of the rabbit β-globin poly-adenylation site (22) . The resultant TG construct was re-sequenced to ensure the absence of errors. The TG construct was freed out of the pCAGGS vector with SalI and PstI (Fig. 1A) and used for pronuclear microinjection to create GFPdgn TG mice in the FVB/N inbred background. TG founders were initially identified with genomic Southern blots using GFPdgn coding sequence as the probe. Subsequent genotyping was performed with PCR using a primer pair: 5′-GCGATGCCACCTAC GGCAAGC-3′ and 5′-GTGGTCGGCGAGCTGCACGCT-3′, which are GFPdgn-specific. All GFPdgn mice used for experiments in the present study were heterozygous TG mice from the F1 and F2 generations. Institutional guidelines were followed in the care and use of experimental animals.
Echocardiography
Transthoracic echocardiography was performed on 2-and 12-month-old GFPdgn TG mice and non-TG (NTG) controls using a high-resolution Vevo600 echocardiogram system with a 30 MHz transducer (Visual Sonics, Toronto, Canada). Anesthesia of the animals was maintained on a minimum dose of isoflurane (1-2%) via a nose cone throughout the procedure. After shaving of the left hemithorax, the mice were positioned supine on a heated platform with a slight left tilt. A two-dimensional (2-D) parasternal short-axis image of the left ventricle was recorded at a depth setting of 12.7 mm at the level of the papillary muscles. A 2-D guided M-mode image was then acquired perpendicular to the anterior and posterior walls at a frame rate of 30 Hz. Measurements of diastolic and systolic wall thicknesses and left ventricular end-diastolic and end-systolic chamber dimensions were made from leading edge to leading edge of the tracings. Ejection fraction (EF), percentage fractional shortening (FS), and left ventricular mass were derived from the above primary measurements and the accompanying software.
Protein detection
Total protein or the soluble fraction of protein was extracted from myocardium of the left ventricle of mouse hearts, from the tissue of other organs, or from cultured adult mouse ventricular myocytes, where applicable. The protein concentration was determined by using bovine serum albumin as the standard. SDS-PAGE and Western blot analysis were performed as described previously (14) .
RNA analyses
Total RNA was isolated from various tissues using TRIREAGENT from Molecular Research Center, Inc. (Cincinnati, OH). GFPdgn cDNA and a nick-translation kit (Roche, Indianapolis, IN) were used to make probes to detect GFPdgn transcripts in major organs by Northern blots and dot blots as described previously (23) . Reverse transcription-polymerase chain reactions (RT-PCR) were also used to examine GFPdgn expression in the major organs. The PCR primers are the same as those used for genotyping. Total RNA for RT-PCR was pretreated with DNase I (Invitrogen, Carlsbad, CA) to remove potential genomic DNA contamination. The transcripts of the natriuretic peptide A (ANF) and B (BNP) in ventricular myocardium were assessed using RNA dot blot analysis as previously reported (24) .
Peptidase activity assays
The synthetic fluorogenic peptide substrate Suc-LLVY-aminomethyl coumarin (AMC, 25 μM) from CALBIOCHEM (San Diego, CA), Z-LLE-β naphthylamide (NA, 25μM), and Bz-VGR-AMC (40 μM) from BIOMOL were used, respectively, for measuring chymotrypsin-, caspase-, and trypsin-like activities. Assays were performed by using 10 μg of soluble protein in a total volume of 200 μl. The assay buffer was composed of 25 mM Tris-HCl at pH 7.5 (12, 25) . Following incubation at 37°C for 90 min, the reaction was quenched by adding 300 μl of ethanol. A 2.0 ml aliquot of H 2 O was then added, and the fluorescence intensity of the samples was evaluated using a Perkin Elmer LS 55 luminescence spectrometer. The excitation/emission wavelength (nm) is 350/435 for AMC and 333/406 for NA products. Peptide cleavage reactions were performed in the absence or presence of the proteasome-specific inhibitor MG-132 (N-Cbz-LLL, 20 μM, CALBIOCHEM) for chymotrypsin-like and caspase-like activities or epoxomicin (20 μM, CALBIOCHEM) for trypsin-like activity. The portion of activities that was inhibited by respective inhibitors is attributed to the proteasome.
Fluorescence spectrometry
Soluble protein extracts (150 μg) from ventricular myocardium diluted in 2 ml of pure water were used for the emission spectrum scan with the excitation wavelength set at 489 nm (specific for GFP) using a Perkin Elmer LS 55 luminescence spectrometer.
Fluorescence microscopy
Cryosections from paraformaldehyde-fixed mouse hearts, lungs, liver, cerebrum, and kidneys were visualized using an Olympus I-70 confocal microscope. Green fluorescence images from different samples in the same organ were obtained using the same optical and imaging settings. To monitor GFPdgn changes in live cultured adult mouse ventricular myocytes that were treated with a proteasome inhibitor or vehicle control, an inverted epi-fluorescence microscope equipped with an IX-71 (Olympus, Melville, NY) digital camera was used.
Culture cardiomyocytes isolated from adult GFPdgn mice
The isolation of adult mouse cardiac myocytes was based on established procedures with some modifications (26) . Briefly, the heart is cannulated through the aorta and connected to a Langendorff perfusion system. Calcium-free perfusion buffer is used to arrest the heart; collagenase-based digestion buffer dissociates myocytes. Finally, calcium is reintroduced to produce quiescent, rod-shaped myocytes. The myocytes are plated and incubated in MEM at 37°C, 2% CO 2 until use.
Statistics
Results are presented as mean + SD unless indicated otherwise. Significance levels were calculated using Student's t test or one-way ANOVA, followed by the Scheffe test, where applicable. P < 0.05 was considered significant.
RESULTS
Creation of GFPdgn stable TG mouse lines
Similar to GFP u reported previously by Bence et al. (12), GFPdgn was created by fusion of the yeast CL1 degron to the carboxyl terminus of an enhanced GFP. GFPdgn is 16 amino acid residues (S240 through G255) shorter than GFP u . These amino acid residues are not a part of wild-type GFP but were included in the carboxyl terminus of conventional enhanced GFP construct for introduction of multiple cloning sites. The cDNA of GFPdgn was placed behind a ubiquitous promoter (Fig. 1A ) to obtain expression in essentially all types of tissues. Selection of a reporter similar to a previously described GFP u reporter UPS substrate for generation of TG animals was based on the following: (i) like GFP u , GFPdgn contains a strong degron that is recognizable by mammalian UPS; (ii) GFP u is soluble and well tolerated in mammalian cells; and (iii) accumulation of GFP u is indicative of proteasomal inhibition in HEK cells and rat ventricular myocytes (12, 14) . Genotyped with genomic DNA extracted from tails, 10 mice (F0) in the FVB/N background from pronuclear injections were identified as GFPdgn transgene positive. Subsequent breeding proved germ-line transmission in 8 of them. From F1 to F2 and subsequent generations, normal litter sizes and a mendelian inheritance pattern consistent with insertion of the transgene in a single chromosome locus were observed. After screening GFPdgn expression in the heart and other organs, three stable GFPdgn TG mouse lines (lines 1, 2, and 3) were established. Both transcript and protein analyses demonstrate that GFPdgn transgene is ubiquitously expressed in these stable lines (Fig. 1 ). RT-PCR (Fig. 1B) and Northern blot (data not shown) analyses reveal that GFPdgn is expressed in all the major organs examined, including the heart, lungs, liver, kidney, spleen, brain, small intestine, and skeletal muscle. Western blot analysis shows that baseline GFPdgn protein levels in the heart are different among the three stable mouse lines with the highest in line 3, the lowest in line 1 and the intermediate in line 2 ( Fig. 1C) .
No discernible cardiac phenotype in the GFPdgn TG mouse lines
One of the main goals of this study is to test whether the GFPdgn TG mouse model is suitable for monitoring in vivo UPS function in major organs, especially the heart. A prerequisite for the validity of this model to monitor UPS function in the heart is that expression of GFPdgn does not, by itself, affect the heart. We have monitored the F1 generation of the three stable GFPdgn TG lines for over one year. No cardiac abnormality is observed. Neither gravimetric analysis (Table 1 ) nor 2-D guided M-mode echocardiography analyses (Table 2) showed statistically significant difference in any of the parameters that reflect the morphometry and function of the heart.
Reactivation of some of the fetal genes, such as natriuretic peptide A and B (ANF and BNP, respectively) in adult mouse ventricles, has been considered as a response at the molecular level to cardiac pathology or as the molecular markers of cardiac hypertrophy (27, 28) . Using welldocumented RNA dot blot analysis with transcript-specific oligonucleotide probes (23, 28), we did not detect statistically significant difference in expression of ANF and BNP between GFPdgn TG and NTG littermates (data not shown). To demonstrate the sensitivity of the RNA dot blot assays, we simultaneously measured the transcript levels of these fetal genes in the ventricles of a previously described desmin-related cardiomyopathy (DRC) mouse model. We could confirm previously reported fetal gene reactivation in the DRC mouse hearts (data not shown) (29) .
Response of GFPdgn protein to systemic proteasomal inhibition
Tests in cultured NRVMs and human embryonic kidney (HEK) cells showed that fusion of degron CL1 to the carboxyl terminus of conventional GFP (GFP u ) renders the GFP a specific substrate for the UPS (12, 14). Changes in GFP u protein abundance displayed an inverse linear correlation to UPS activities in cultured NRVMs (14) . To test whether a similarly engineered GFPdgn protein behaves in the same manner in various organs of mice as GFP u in cultured NRVMs and HEK cells, systemic proteasomal inhibition was achieved by an intravenous injection of MG-262, a specific proteasome inhibitor (15) . MG-262 was dissolved in 60% DMSO in saline. Mock-treatment used 60% DMSO in saline. As estimated by peptidase activity assays at 20 h after MG-262 administration (5 μmol/kg body weight) to line 3 GFPdgn mice, the chymotrypsin-like activity of the 20S proteasomes in the heart, lungs, skeletal muscle and liver was inhibited by 75%, 60%, 70%, and 50%, respectively ( Fig. 2A) . In response to the proteasomal inhibition, GFPdgn protein levels were significantly increased in all the organs examined, including the heart, lungs, liver, kidneys, brain, spleen, small intestine, and skeletal muscle (Fig. 2B, C) . The increase in GFPdgn protein levels was measurable by not only Western blot analysis (for all the organs, Fig. 2B , C) but also fluorescence spectrometry (at least for the heart, Fig. 3A ). Intracellular GFPdgn protein distribution is readily visible with direct fluorescence microscopy (Fig. 3B) . The proteasomal inhibition-induced increase in GFPdgn protein was relatively homogenous among different cells in the heart and kidneys but appeared to be heterogeneous in the lungs, liver, and cerebrum (data not shown). The heterogeneity may arise from different levels of GFPdgn expression among different cell/tissue types that make up the organs or different degrees of proteasomal inhibition induced by the same concentration of proteasome inhibitors. To rule out the possibility that the response is specific to MG-262, a proteasome inhibitor of a different class, clasto-lactacystin-β-lactone (CLBL) was also tested. The chymotryptic activity was inhibited by approximately 30% in both the heart and lungs at 20 h after CLBL was intravenously injected (1 μmol/kg body weight). Significant increases in GFPdgn protein levels in representative organs (the heart, lungs) were also observed at this much milder proteasomal inhibition by CLBL (Fig. 2C) .
Dox decreases cardiac GFPdgn protein
It is well known that Dox induces cardiomyopathy, but the underlying mechanism is not completely elucidated. To test whether Dox modulates UPS function in the heart, we examined GFPdgn protein levels at 6 and 24 h after an intraperitoneal injection of Dox (25 mg/kg body weight) using Western blot analysis. GFPdgn protein levels in the heart were significantly reduced in the Dox-treated group at both 6 and 24 h after the injection, compared with the mocktreatment group (Fig. 4A ), but the steady-state transcript levels of GFPdgn were not significantly changed at 6 h after administration of Dox (Fig. 4B) . Interestingly, the activities of all the three peptidases (chymotrypsin-like, caspase-like, and trypsin-like) of the 20S proteasomes in the heart were not increased at either 6 or 24 h after Dox treatment. On the contrary, chymotrypsin-like and caspase-like activities were decreased at 24 h after Dox treatment and the chymotrypsin-like activity was decreased at 6 h as well (P<0.05, 0.01). These decreases are moderate but statistically significant (Fig. 4C) .
Cultured cardiomyocytes from adult GFPdgn mice as a platform to study UPS function
To evaluate potential use of cultured cardiomyocytes from adult GFPdgn TG mice as a platform to study UPS function, we examined the effect of various proteasome inhibitors on the protein levels of GFPdgn in the cultured cardiomyocytes. Proteasome inhibition by each of the three different specific inhibitors, MG-132, MG-262, and CLBL, caused marked increases in GFPdgn protein in the cells as determined by Western blot analysis (Fig. 5A ) and fluorescence microscopy (Fig. 5B) . These data suggest that cultured cardiomyocytes from adult GFPdgn mice represent an alternative platform for in vitro studies on UPS function. Using this platform, we tested the direct effects of Dox treatment on cardiac myocytes at cellular level. We treated the cultured cardiomyocytes isolated from 2−3 months old GFPdgn mice with various doses of Dox (0.1-1.0 μM). The GFPdgn protein levels in the cells were significantly reduced by Dox treatment in a dose-dependent manner (Fig. 5C ). This effect was detectable within as early as 1 h of treatment (0.5 μM, data not shown). At 3 h after treatment, the reduction of GFPdgn was detectable with a Dox dose as low as 0.1 μM (Fig. 5C ). This decrease was completely abolished by proteasomal inhibition (Fig. 5D) , suggesting enhancement of UPS-mediated protein degradation by Dox. The notion that Dox enhances UPS proteolytic function is further supported by induction of additional decreases in GFPdgn protein levels by Dox in cardiomyocytes pretreated with cycloheximide (20 μM) to block protein synthesis (Fig. 5E ).
DISCUSSION
UPS dysfunction potentially plays significant roles in many diseases. Data collected from tissue culture and indirect observations from animal models of human disease and, in some cases, from human biopsies and autopsies have suggested that UPS dysfunction may be involved in the pathogenesis of neurodegenerative disease, especially those associated with protein misfolding and aberrant protein aggregation, such as Alzheimer's, Huntington's, and Parkinson's diseases (30) (31) (32) . UPS derangement has also been suspected in heart disease such as dilated and ischemic cardiomyopathies, the major causes of congestive heart failure (33) (34) (35) . Due to explosive advances in genetic engineering, especially mouse transgenics in the past decade, many excellent mouse models of above-mentioned human diseases have been developed (29, (35) (36) (37) (38) . However, the research into the involvement of the UPS in physiological and pathological processes demands a dependable method to assess in vivo changes in the proteolytic function of the UPS (39) . This urgent need prompted us to create a TG mouse model that can be conveniently and reliably used to directly monitor dynamic functional changes of the UPS in vivo. In the present study, we have created and validated such a mouse model. These mice ubiquitously express a surrogate protein substrate (GFPdgn) for the UPS in all major organs. To take advantage of this new model, we further demonstrated that cardiomyocytes isolated from adult GFPdgn TG mice can be effectively used in a primary culture setting to investigate the effect of a pharmacological agent on the UPS. Assisted by these new in vivo and in vitro tools, we have discovered that Dox, a potent anti-tumor agent of the anthracycline family, significantly enhances UPS proteolytic function in cardiomyocytes and in the heart, suggesting UPS hyperfunction as a potential underlying mechanism for Dox cardiotoxicity.
GFPdgn mice as a reliable readout for UPS function in all major organs
Degradation of a cellular protein by the UPS requires ubiquitination of the protein molecule by a cascade of enzymatic reactions and the degradation of the ubiquitinated protein by the 26S proteasome (1). The proteolytic activity of the proteasome is largely regulated by controlling the access of target proteins to the lumen of the 20S core where peptide cleavage takes place (1). Therefore, to evaluate the proteolytic function of the entire UPS, a full-length reporter protein substrate is required. The essential criteria for an optimal reporter substrate to be used for generation of TG animals should include the following: (i) it is easy to be detected and quantified; (ii) its degradation is through the UPS and has a short half-life in the cell; (iii) its synthesis is ubiquitous and relatively stable; (iv) its degradation is not subject to any intrinsic regulation other than the status of UPS function; and (v) it is well tolerated by the cell. None of the endogenous proteins would be a good candidate for this reporter because the synthesis and degradation of each of them are subject to inherent regulations in addition to UPS function. A few previously described surrogate substrates for the UPS fulfill these criteria well (12, 13). One of them is GFP u , an enhanced GFP modified via carboxyl fusion of the degron CL1 (12). It was shown that GFP u has a half-life of 30 min in HEK cells, while the half-life of conventional GFP is ~10 h (12). Its degradation in cultured HEK cells and NRVMs depends exclusively on the UPS (12, 14) . Therefore, we chose to create a mouse model expressing GFPdgn, which is similar to GFP u . Transcript and protein analyses consistently showed that GFPdgn is ubiquitously expressed in all the major organs of GFPdgn mice. More importantly, the protein abundance of GFPdgn in all the major organs showed responsive increases upon systemic proteasomal inhibition (Fig. 2) . The increase is readily measurable by a number of conventional methods, including Western blot analysis (Fig. 2B, C) , fluorescence spectrometry (Fig. 3A) , and direct fluorescence microscopy (Fig. 3B) .
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Robust cardiac overexpression of conventional GFP was shown to cause dilated cardiomyopathy (DCM) in mice (40) . It is thus a legitimate concern that expression of GFPdgn might induce cardiac pathology, thereby affecting the use of this model. To address this issue, we have observed GFPdgn mice, especially those of the intermediate and highest expression lines (line 2 and 3) for over 1 year. No anatomic or functional abnormalities have been detected. Gravimetric analysis of the heart showed no cardiac hypertrophy at 1, 3, and 12 months of age (Table 1) . Echocardiography at 2 months and 12 months of age did not detect morphometric and functional abnormalities ( Table 2) . Reactivation of the fetal gene program such as ANF and BNP in the ventricles is often associated with cardiac pathology (27, 28) . Transcript analysis did not show an increase in ANF and BNP expression in the ventricles of any of the 3 stable GFPdgn mouse lines. The reason for the phenotypic difference between GFPdgn TG mice and conventional GFP TG mice is not very clear, but the following two aspects of difference are perhaps important: (i) the TG promoter (the murine α-myosin heavy chain promoter) used for driving overexpression of conventional GFP in the heart of mice reported by Huang et al. (40) is much more robust than the one used for GFPdgn overexpression in the mouse lines described here; (ii) the half-life of GFPdgn is considerably shorter than that of conventional GFP; therefore, GFPdgn less likely accumulates at high levels in the heart or any other organs.
To test whether overexpression of GFPdgn, by itself, affects proteasomal function, the chymotrypsin-like activities, which are the most sensitive and important proteasomal peptidase activities, were measured in representative organs of the highest GFPdgn expressing mice (line 3). Compared with NTG littermates, no statistically significant difference was detected ( Fig. 2A) . Taken together, GFPdgn expression is well tolerated in each of the 3 stable TG lines and shows no adverse effects on the heart.
Creation of GFPdgn mouse model was not planned to overcome the shortcomings shown in the Ub G76V -GFP mouse model reported recently by Lindsten et al. (15) . This is because the generation of GFPdgn mice was independently started immediately after the GFP u construct was reported by Bence et al. (12), which was 2 years before Ub G76V -GFP mice were reported. However, characterization of our GFPdgn mice has revealed that this model has a remarkably exciting advantage over Ub G76V -GFP mice. As indicated by Lindsten et al., systemic proteasome inhibition by MG-262 (5 μmol/kg) did not discernibly accumulate Ub G76V -GFP protein in the heart, brain, and skeletal muscle (15) . By contrast, GFPdgn protein in the adult heart, brain and skeletal muscle (Figs. 2 and 3) , as in other major organs, displayed a significant increase upon a similar degree of, or even milder proteasomal inhibition than what was used to test the Ub G76V -GFP mouse model by Lindsten et al. (15) . The increased GFPdgn protein levels are clearly evidenced by not only Western blot analysis (Fig. 2B, C) but also fluorescence spectrometry (Fig. 3A) and direct fluorescence microscopy (Fig. 3B) . Notably, a growing body of evidence suggests UPS dysfunction in a diverse group of disorders of the brain, heart, and skeletal muscle, such as Alzheimer's, Huntington's, and Parkinson's diseases, congestive heart failure resulting from dilated and ischemic cardiomyopathies, desmin-related myopathy and cardiomyopathy, and muscle wasting in muscular dystrophy and cachexia (32) (33) (34) (35) (41) (42) (43) (44) . Hence, it is very clear that GFPdgn mice are much better suited for monitoring in vivo UPS proteolytic function than Ub G76V -GFP mice.
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Dox activates the UPS in the heart
Clinical use of Dox has been considerably limited by its cardiotoxicity (16) . Chemotherapy with Dox causes irreversible cardiac damage and even congestive heart failure (16) . Despite extensive efforts, the search for the underlying mechanisms and preventive measures has not been satisfactory (17, 18) . Several recent studies implicated that Dox might interfere with UPSmediated proteolysis (19) (20) (21) . Applying our newly developed GFPdgn mouse model, we have discovered that the abundance of GFPdgn protein in the heart of intact mice (Fig. 4A) was markedly reduced by Dox treatment at both 6 and 24 h, while the steady state mRNA level of GFPdgn was not significantly affected at 6 h after the treatment (Fig. 4B) . This finding suggests that the decrease in GFPdgn protein is likely due to enhanced UPS-mediated degradation. Interestingly, proteasomal peptidase activities were not increased by Dox treatment. On the contrary, the chymotrypsin-like activity was moderately decreased at both 6 and 24 h after Dox treatment. The caspase-like activity was decreased at 24 h (Fig. 4C) . Despite moderate decreases in some of the peptidase activities of the 20S proteasomes, the net effect of Dox treatment on the entire UPS in the heart was enhanced proteolytic function. This suggests that the main mechanism for Dox to enhance UPS proteolytic function is by acting on the part outside of the β-rings of 20S proteasomes.
Using cultured cardiomyocytes from adult GFPdgn mice, we could further dissect the effect of Dox on UPS in cardiomyocytes (Fig. 5 ). Similar to in vivo observations, GFPdgn protein abundance in the cultured cells was significantly reduced by Dox treatment in a dose-dependent manner (Fig. 5C ), indicating that Dox can either directly decrease the synthesis or enhance the degradation of GFPdgn. Dox-induced decrease in GFPdgn protein was abolished by blocking proteasome-mediated protein degradation (Fig. 5D ) but persisted when overall protein synthesis was inhibited by pretreatment of cycloheximide (Fig. 5E) , suggesting that the Dox-induced GFPdgn decrease is indeed caused by increased degradation. These findings prove that Dox can directly enhance UPS function in cardiomyocytes. Excessive proteolysis can conceivably destroy the homeostasis in cardiomyocytes, thereby damaging the structure, disrupting metabolism, altering signaling processes, and impairing the function of the heart. Thus, these findings suggest that enhanced UPS function is potentially an important mechanism underlying acute cardiotoxicity of Dox. Both Dox and proteasome inhibitors have proven to be effective in treating cancer. Hence, combining use of Dox with a proteasome inhibitor in anti-cancer chemotherapy may prevent or attenuate Dox-induced cardiotoxicity.
In summary, in addition to facilitating physiological, pharmacological, and pathogenic studies on the UPS, the GFPdgn mouse model and associated new in vitro methodologies developed and validated in the present study will also conceivably benefit therapeutic exploration, including screening for new measures to modulate UPS function. Proteasome inhibition has proven to be very effective in suppressing cell proliferation in treating cancer and preventing restenosis (45) (46) (47) . Since UPS malfunction appears to be a nodal pathogenic mechanism (35, 48, 49) , it is reasonable to postulate that controllable UPS activation would help more effectively treat protein surplus diseases. Note that TG expression of GFPdgn did not significantly affect the peptidase activity, while MG-262 markedly inhibited chymotrypsin-like activity in the heart, lungs, skeletal (Sk.) muscle, and liver that were examined. AU: arbitrary unit. B) Representative Western blots for GFPdgn in indicated organs of mice described in (A). For each organ, equal amounts of total protein from an MG-262 treated (+) and a DMSO-treated (-) mouse were used. Total proteins loaded to each lane of the skeletal (Sk.) muscle, heart, lungs, small intestine (Intestine), liver, kidney, brain, and spleen were 5, 10, 30, 30, 50, 50, 60, and 60 µg, respectively. For the NTG control lane, 50 µg of skeletal muscle protein were loaded. Note that GFPdgn levels in mock-treatment mice varied substantially among different organs, but all clearly displayed significant increase upon proteasomal inhibition by MG-262. C) Western blot analysis shows significant increases in GFPdgn in representative organs (the heart and lungs) in response to proteasome inhibition by a different proteasome inhibitor, clasto-lactacystin β-lactone (Lactacystin). Analyzing GFPdgn fluorescence by spectrometry and confocal microscopy. A) GFP-specific fluorescence emission spectra of myocardial protein extracts from NTG (green), MG-262 treated (red), and DMSO-treated (blue) GFPdgn TG mice described in Fig. 2A . Myocardial-soluble protein (150 µg) in 2.0 ml water was used for an emission scan with the excitation wavelength set at 489 nm. Note that a characteristic green fluorescence emission peaked at 510 nm was clearly unique to GFPdgn TG mice. In agreement with Western blot analysis of GFPdgn, the intensity of this spectrum was increased by a factor of 2.8 by MG-262 treatment, compared with the DMSO-treated group. B) Direct green fluorescence micrographs of cryosections from the heart of NTG mice, or GFPdgn TG mice (line 3) that were treated as described in (A). Scale bar = 100 µm. clear reduction of GFPdgn protein levels in the heart at 6 (Dox 6 h) and 24 h (Dox 24 h) after Dox treatment (25 mg/kg, i.p.). B) Total RNA was isolated from ventricular myocardium and skeletal muscle (Sk. M.) of the quadriceps femoris at 6 h after Dox or mock treatment. RNA dot blot analysis of GFPdgn and GAPDH used radioactive-labeled transcript-specific oligonucleotide probes. GAPDH transcript levels serve as a loading control. Three mice of line 1 and 1 mouse of line 3 were included for the heart, while only mice of line 1 were included for the skeletal muscle. Densitometry analyses showed no statistically significant difference between mock and Dox-treated groups in both the heart and skeletal muscle (data not shown). C) The activities of the three indicated proteasomal peptidases in myocardial crude protein extracts were assayed using synthetic fluorogenic substrates. Note that the activities showed a tendency to decrease rather than increase at 6 and 24 h after Dox treatment. Mean + SE are plotted, and the number of mice for each group is indicated in the parenthesis of the legend. **P < 0.05, *P < 0.01, compared to the control group, one-way ANOVA followed by the Scheffe test. were isolated and cultured from adult mice as previously reported (26) . A) Representative Western blot images showing that proteasome inhibition (12 h) by clasto-lactacystin β-lactone (CLBL, 0.5 µM), MG-132 (10 µM), and MG-262 (100 nM) respectively, increased GFPdgn protein levels significantly in the cultured cells. B) Direct fluorescence micrographs taken at 10 h after MG-132 (10 µM) or control treatment. C) A representative Western blot image and the densitometric data (the bar graph below the image) of four independent experimental repeats show that Dox treatment significantly reduced GFPdgn level in a dose-dependent manner. The GFPdgn signal of the mock-treatment control (0 µM Dox) lane was set as 100 AU. Other lanes were normalized to the mock-treatment control lane. *P < 0.05, **P < 0.01, compared with the mock-treatment, paired Student's t test. D) The decrease in GFPdgn protein levels was completely abolished by proteasomal inhibition by MG-262 (100 nM). The densitometry data of the Western blots from four independent repeats are plotted. The density of the GFPdgn band in the control group (Saline) was set as 1.0 AU, and the GFPdgn band intensity of other lanes was normalized to the control lane in each experiment. Dox1.0 and Dox0.5: cells treated with Dox at doses of 1.0 and 0.5 µM, respectively; Dox+MG: cells treated with Dox (0.5 µM) and MG-262 (100 nM); MG: cells treated with MG-262 (100 nM) alone. E) The effect of protein synthesis inhibition by cycloheximide (CHX) on Doxinduced decrease in GFPdgn protein. Cells are pretreated with CHX (20 µM) or DMSO (vehicle control) for 1 h before Dox (0.5 µM) or equal volume of saline (vehicle control) was applied. CHX caused a time-dependent decrease in GFPdgn protein levels, while Dox induced additional reduction of GFPdgn levels. The comparison of GFPdgn levels measured by Western blot (a) between the control (CHX+Saline) and experimental (CHX+Dox) groups at different time points was illustrated by the bar graph (b). The statistical data were from four independent experiments (*P<0.05; **P<0.01). Mean + SD; paired Student's t test.
